Full Press Release Details
PREDICTIVE PRECISION PROTEOMICS (AP3): DRUG-TAILORED PATIENT SELECTION FOR CLINIC AL SUCCESS CORPORATE PRESENTATION APRIL 2023
ACRIVON THERAPEUTICS: DRUG -TAILORED PATIENT SELECTION AIMING TO
OVERCOME THE KEY ATTRITION FACTOR PREVENTING CLINICALLY ACTIVE DRUGS FROM REACHING MARKET AP3 Platform OncoSignature ACR-368 (Prexasertib) Pipeline - Acrivon's proprietary - Clinically active (15-20% - Two co-crystallography- and - Our
proprietary predictive proteomics-based predictive ORR) Phase 2 DNA Damage AP3-driven preclinical drug-tailored biopsy test precision medicine platform Response (DDR) inhibitor programs targeting WEE1 - Extensively evaluated in licensed from Eli
Lilly & Co. and PKMYT1, proximal and - Applied where NGS/genetics prospective preclinical studies, redundant DDR nodes is insufficient and for our - Now being developed with including prediction on internal pipeline OncoSignature patient -
Single digit nM inhibitors, blinded pretreatment tumor selection for increased ORR wholly-owned, opportunity biopsies from past trials with registrational intent for AP3 patient selection and DNA resulting in ORR 47% and 58% pipeline combinations
OncoSignature Prediction: OncoSignature Prediction: Predicted Predicted Non-Responders Responders 1.2 RNA Non-Responders Responders 0.9 Protein 0.6 P Dysregulated Protein 0.3 P Drug 0.0 Dysregulated (0.3) Pathways (0.6) OROR RR == 0% 0% ORR OR = R 4
= 47 7%% CANCER (0.9) PD SD PD PD PD SD SD SD PD SD SD SD SD SD SD SD PR PR PR PR PR PR PR 2 ACRIVON THERAPEUTICS Tumor fractional change
ACCOMPLISHED LEADERSHIP TEAM Rasmus Holm-Jorgensen Erick Gamelin, M.D.,
Ph.D. Kristina Masson, Ph.D. Peter Blume-Jensen, M.D., Ph.D. Eric Devroe, Ph.D. Chief Financial Officer Chief Medical Officer Co-Founder, CEO, Acrivon AB CEO, Founder Chief Operating Officer EVP Business Operations Novo Nordisk Finance and
IR Founder and CEO, Opsonix Executive Serono, Merck & Co., Professor, CEO, large national Cross-functional Leadership Synageva pipeline expansion Business executive MD Anderson Daiichi Sankyo
cancer center and hospital Merrimack Pharmaceuticals, and $9bn sale to Alexion Cancer Center and Metamark CSO Metamark - Marketed Executive Amgen, Pfizer, Dynavax, MIT/BROAD Kiniksa founding team, IPO EIR Wyss
Institute, Harvard prostate proteomic test ProMark MacroGenics; CMO STEP Pharma Founder and CEO, OncoSignature AB and commercial launch Associate, Flagship Pioneering Inventor AP3 pt. selection platform Led >100 ph
1-3 oncology trials (acquired by Acrivon Therapeutics) Joon Jung, Ph.D. John van Duzer, Ph.D. Jeremy Barton, M.D., M.R.C.P. David Proia, Ph.D. Katie Peterson, C.P.A. Michail (Misha) Shipitsin, Ph.D. VP, Head, Data Science Chief Medical Advisor VP,
Drug Discovery and Biology VP, Finance and Accounting VP, Biomarker Development SVP, CMC VP/Head, Theonys, Inc. Head, Financial Planning and Head clin. biomarkers, Metamark CMO Mirati VP/SVP Acetylon,
Collegium, VP, Rome Therapeutics, C4 Analysis Wave Life Sciences, Cyclerion/Ironwood Scientific lead on marketed, Therapeutics, Biogen- Eloxx, Mersana, ActivBiotics Therapeutics Previously Merck & Co., Spero Therapeutics,
and prostate test, ProMark Idec, Effector Inventor of HDACi's Previously Synta, Astra- J&J, Triad Therapeutics Merrimack Pharmaceuticals Expert digital imaging & clinical Head Early Oncology
Ricolinostat and Citarinostat Zeneca, Boston Biotech Audit Manager, CPA Ernst & Multiple recognition awards protein biomarker tests Drug Development Pfizer and COX2i Lumiracoxib Multiple recognition awards Young LLP 3
ACRIVON THERAPEUTICS
ACRIVON THERAPEUTICS AT A GLANCE Development Site (Boston)
Precision-Proteomics Site (Lund/Copenhagen) Drug and clinical biomarker assay development Early pipeline drug programs Clinical trials BM identification and drug profiling Market access pending approval
Mass spectrometry OUR PROTEOMIC HUB IS LOCATED IN OUR HQ IS LOCATED IN BOSTON - MEDICON VALLEY - NORTHERN EUROPE`S ACCESS TO LEADING DRUG DISCOVERY, LEADING LIFE SCIENCE CLUSTER BIOTECH, AND PHARMA Peter Blume-Jensen Kristina Masson Jesper
V. Olsen CEO, President, Academic Co-Founder. EVP, Bus Ops, Co-Founder Novo-Nordisk Foundation Site Head and Protein Center, Cph. Co-Founder Acrivon was founded in early 2018 and is backed by top-tier investors 4 ACRIVON THERAPEUTICS
ACRIVON PREDICTIVE PRECISION PROTEOMICS, AP3 DNA Genomic Biomarkers are
useful for patient selection in the smaller subset of cancers (<10%) with single gene driver mutations or known synthetic lethal context* RNA Protein P Dysregulated CANCER IS CAUSED BY DYSREGULATED PROTEIN ACTIVITY Protein Drug P Acrivon's
AP3 platform directly measure the disease-driving, dysregulated proteins and is designed to enable an exact match with the drug mechanism-of-action independent of genetic alterations Dysregulated Pathways (Acrivon meaning: "Exact,
Accurate") CANCER *Oncogenic Kinase Signaling: Blume-Jensen, P. and Hunter, T. Nature (2001) Synthetic lethality as an engine for cancer drug target discovery: Huang, A. et al. NatRevDrugDisc (2020) 5 ACRIVON THERAPEUTICS
AP3 PLATFORM ADDRESSES HIGH UNMET NEED BEYOND NGS -BASED PRECISION
MEDICINE Acrivon Positioned to Increase Precision Oncology Market Size Current Precision Oncology Approaches Only Scratching the Surface 72 unique approvals Precision Oncology 1.0 51 drugs 31 genomic indications Approved indications: Approved
indications: 18 cancer types HER2+ Breast Cancer CML (BCR-ABL) Only 5% of patients respond st HER2+ Gastric Cancer Ph+ ALL 1 Gen Precision Oncology Currently Unaddressed Precision Oncology 2.0 Solid Tumors (NTRK)) IDH mutation in AML NSCLC (NTRK)
and NSCLC (KRAS G12C) CRC (ROS1, ALK) Class II and III BRAF 95% of patients are currently unaddressed by Bladder (FGFR3) Solid Tumors (NRG1) kinase alterations: N/A traditional genetics-based precision oncology Predictive Precision Proteomics Aiming
to make targeted therapeutic solutions available to broader group of cancer patients Sources: Company Filings, ACS, CDC, NCI, Wall Street Research 6 ACRIVON THERAPEUTICS
AP3 PLATFORM: DRUG RESPONSE PREDICTION IN INDIVIDUAL PATIENTS
PROPRIETARY 3 -STEP WORKFLOW INTEGRATING PROVEN TECHNOLOGIES Drug OncoSignature STEP 1 STEP 2 STEP 3 Predicted Predicted THERAPEUTIC PACKAGE PATIENT RESPONDERS BIOMARKER IDENTIFICATION Non-responder Responder Acrivon drug with predictive BM assay
Optimal indications and combinations CLASS 1 BM CLASS 2 3 AP DRUG PROFILING BM HIGH RES PROTEOMICS BY MS Resistant Sensitive + No benefit Benefit CLASS 3 OncoSignature BM CLINICAL SIGNATURE ASSAY PROSPECTIVE RESPONSE PREDICTION ON
PRETREATMENT BIOPSY 3-6 BIOMARKERS Patients without biomarkers critical BIOMARKER VALIDATION for drug sensitivity efficiently excluded CELL LINES, PDX, HUMAN TISSUE "Disease Pathway-Based Method to Generate Biomarker Panels Tailored to
Specific Therapeutics for Individualized Treatments": EP 2 229 589, issued June 10, 2015; US2017/0067877A9, pending. OncoSignature is a Registered Trademark: US Reg. No. 5,718,472; Int. Cl. 5, 42. Intl. Reg. 1382289 \ 7 ACRIVON
ACRIVON PIPELINE Anticipated Preclinical Phase 1 Phase 2 Phase 3 Next
Milestone Single-Arm Trials Based on OncoSignature Prediction ACR-368 Monotherapy Platinum-Resistant Ovarian Cancer LDG Combination ACR-368 Monotherapy Initial Clinical Readouts in Endometrial Cancer Second Half 2023 LDG Combination ACR-368
(CHK1/CHK2) ACR-368 Monotherapy Bladder Cancer LDG Combination Staggered Development Under Same Master Protocol Trial Design + ACR-368 Monotherapy HPV SCC (anal, H&N Option to Initiate in 2023 and cervical cancer) LDG Combination IND-enabling
studies WEE1 Inhibitor in 2023 IND-enabling studies PKMYT1 Inhibitor in 2023 Notes ACR-368 Monotherapy Registrational intent Phase 2 single arm trials based on predicted sensitivity to ACR-368 monotherapy in OncoSignature-positive patients LDG
Combination Exploratory Phase 1b/2 single arm trials of ACR-368 in combination with low dose gemcitabine, or LDG, in OncoSignature-negative patients 8 ACRIVON THERAPEUTICS
ACR -368: A CLINICALLY ACTIVE PHASE 2 CHK1/2 INHIBITOR
ATP-competitive inhibitor of CHK1 (0.9 nM) and CHK2 (8 nM) Good ADME properties, minimal drug-drug interaction (DDI) potential Discovered by Array Biopharma, acquired by Eli Lilly & Company CoM patent exp. Oct., 2030;
Salt-form exp. Apr., 2037 ACR-368 (MW): 365.4 M G 1 G1/S-defective cancers Defective G1/S rely on CHK1-regulated Cancer Checkpoint G2/M Checkpoint cell cycle checkpoints Cell Cycle CHK1 pauses cell cycle to S Phase CHK1 G S 2 Checkpoint enable DNA
repair CHK1 Durable monotherapy activity: Platinum-resistant ovarian and squamous cell cancers (Anal and H&N) Large safety database, favorable safety profile: >1,000 patients treated (~50% mono, ~50% in combination)
Ideal for AP3 method: Proven clinical activity, but requires patient responder identification to achieve sufficient ORR 9 ACRIVON THERAPEUTICS
CLINICAL OVERVIEW OF ACR -368 MONOTHERAPY (PAST DATA) # Indication
Trial ORR (confirmed) Median DoR Reference HGSOC* (BRCA wild type, primarily Phase 2 single center 29% >10 months^ Lee et al, Lancet platinum-resistant) (NCI) Oncology, 2018 HGSOC (BRCA wild type and mutant; Phase 2 multi-center 12.1%
(platinum-resistant) 5.6 months Konstantinopoulos platinum-resistant and refractory) (Lilly) et al; Gynec. Oncol.: 2022 Squamous cell cancer (anal cancer, Phase 1b multi-center 19% HPV+ H&N 7 months (HPV+ H&N) Hong et al, CCR, head &
neck cancer [H&N]) (Lilly) 15% anal cancer 12 months anal cancer 2018 Dosing and Administration 2 IV q14d (RP2D = 105 mg/m ) Safety summary Acceptable safety profile in >1,000 patients - No clinical or regulatory holds imposed
across all clinical studies to date Primary adverse events grade 3 were hematological (manageable neutropenia and thrombocytopenia) Limited grade 3 non-hematological toxicities ( 7% for all AEs)
Drug-related discontinuations <1-2% # *High grade serous ovarian cancer; ^Updated post-publication; Overall response rate; Duration of Response 10 ACRIVON THERAPEUTICS
PAST PHASE 2 TRIALS IN HIGH GRADE SEROUS OVARIAN CANCER NCI
single-center Phase 2 study (N=28) Lilly-sponsored multi-center (46 center, 8 country) Phase 2 study (N=169) Heavily pre-treated patients; median 5 prior lines All lines of prior therapy, BRCA wt and mt, incl. prior PARPi
Pretreatment tumor biopsies mandated Pretreatment tumor biopsies mandated RESULTS RESULTS ORR 29%; mDoR >10 months (post-publication) ORR 12.1% (excl. unconfirmed); mDoR =5.6 months mut mut No genetic correlation
with p53 , DDR , or CCNE1 No correlation with genetic alterations 100 N = 169 PATIENTS COHORT DESCRIPTION PERCENT CONFIRMED ORR (95 % C.I.) Best response 50 Cohort 1 (53) Plat resistant BRCA wt; 3 lines of 11.3 (4.3 to 23.0) (N = 24
evaluable patients) prior therapy 0 Cohort 2 (46) Plat resistant BRCA wt; < 3 lines of 13.0 (4.9 to 26.3) prior therapy (50) Cohort 3 (41) Plat resistant BRCA mt, any line of 12.2 (4.1 to 26.2) therapy (must include prior PARPi ) Cohort 4 (29)
Plat refractory, any BRCA, any line of 6.9 (0.8 to 22.8) (100) therapy Platinum-sensitive Platinum-resistant Platinum-refractory Still on study Study ID Lee et al; Lancet Oncology: 2018 Konstantinopoulos et al; Gynec. Oncol.: 2022 10 14 36 48 7 42 5
46 6 24 35 38 33 23 47 28 17 41 4 31 1 37 40 29 Number of previous lines of therapy 2 5 5 2 5 1 2 3 5 5 6 3 5 6 3 4 4 5 2 13 1 6 5 4 PFS (months) 2.0 2.0 2.0 2.0 2.0 9.5 2.0 2.0 8.0 4.0 8.5 3.0 16.0 4.0 7.5 10.0 13.0 3.5 9.0 7.5 9.0 13.5 12.5 16.5
Mutations in DDR genes CCNE1 gene amplification Past trials suggest unenriched all-comer ORR in HGS ovarian cancer is ~15-20% CCNE1 mRNA upregulation Durable clinical activity in most responders CCNE1 protein overexpression* No
predictive biomarkers identified, need for alternative biomarker approach (ideal for AP3) Positive Negative Amplification Copy number gain Upregulation 11 ACRIVON THERAPEUTICS Best response (%)
DEVELOPMENT OF AP3-BASED PATIENT SELECTION ONCOSIGNATURE TESTS
Technical Validation Functional Validation P-proteomics Cellular MOA (Intended use tissue) (Intended use tissue) Human cancer screening: Quantitative mapping Dose response, BM antibody validation ID of drug-sensitive >20,000 p-sites; knockdowns,
drug by quantitative IF on cancers and proportions 25% drug-related combinations human and PDX of responders samples Final Drug-regulated OncoSignature DMSO 4NQO 4NQO+Prex phospho-sites and OVCAR3 Assay biological processes A2780 Prediction of
drug sensitivity in cancer cell lines and PDX models Target engagement, Pathway visualization cell assays, imaging and reconstitution Patient responder Border: Most regulated Significant Not identified -14 -4 0 4 14 Log2 Intensity ratio prediction
on pre- treatment tumor biopsies Literature and database mining Initial biomarker candidates 12 ACRIVON THERAPEUTICS
ONCOSIGNATURE TESTS: USAGE IN THE CLINIC Pretreatment Treatment
decision tumor biopsy based on patient stratification Predicted Predicted Sample processing Responder Non-responder OncoSignature test Biopsy in Automated tumor FFPE Region-of-Interest block biomarker scoring Pretreatment tumor biopsy
test Compatible with 5 business days turn-around Offered by CDx partner under exclusive license from Acrivon 13 ACRIVON THERAPEUTICS
CONSISTENT ACR -368 ONCOSIGNATURE PERFORMANCE ACROSS PRECLINICAL
STUDIES Tissue ID. BM1 BM2 BM3 Fov060265 0.69 0.79 0.73 Fov050855 0.94 0.71 0.67 Fov041300 0.89 0.23 0.55 Fov060380 0.95 0.62 0.51 Fov060050 0.85 0.23 0.51 Fov041285 0.69 0.19 0.5 Fov100142 0.47 0.76 0.47 Fov050764 0.82 0.22 0.47 Fov041267 0.4 0.36
0.36 Fov100146 0.84 0.57 0.26 Fov060382 0.44 0.45 0.22 Fov041269 0.37 0.21 0.2 Fov060302 0.29 0.22 0.15 Fov020067 0.89 0.38 0.09 Fov100003 0.9 0.89 0.08 Fov050700 0.17 0.17 0.07 Prediction of the fraction of human tumors sensitive to
Fov050139 0.63 0.66 0.05 Fov041138 0.36 0.11 0.05 Fov060152 0.24 0.3 0.03 Fov030062 0.57 0.14 0.02 Fov060133 0.94 0.43 0.01 Fov050666 0.93 0.38 0.01 Fov060371 0.88 0.93 0 Fov020497 0.61 0.43 0 Fov010706 0.54 0.14 0 single agent ACR-368 Fov020386
0.11 0.09 0.12 Fov050734 0.11 0.06 0.08 Fov040872 0.23 0.04 0.36 Fov050659 0.29 0.01 0.02 Fov060293 0.42 0 0 Fov060210 0.1 0.1 0 Fov050840 0.07 0.29 0.01 Fov040855 0.05 0 0.22 o Selection rate 30-40% across lead indications Fov050816 0.04 0.33 0.12
Fov060355 0.04 0.27 0 Fov010252 0.03 0.17 0.02 Fov010682 0.03 0.03 0 Fov060553 0.03 0.02 0.03 71768C3 0.02 0 0 Fov150230 0 0.36 0.12 Fov060308 0 0 0 Identification of additional human tumor types predicted sensitive to single agent ACR-368 o
Endometrial and bladder cancer Prediction of treatment outcome in human PDX models o ORR enrichment to 55%; AUC of 0.88 and 0.9 Two separate, prospectively designed, blinded studies of biopsies from past Phase 2 trials with
ACR-368 in patients with platinum-resistant ovarian cancer o ORR enrichment to 47% (NCI) and 58% (Lilly multi-center) 14 ACRIVON THERAPEUTICS
ACR -368 ONCOSIGNATURE PREDICTION OF DRUG SENSITIVITY: BIOMARKER
QUANTITATION ACROSS HUMAN CANCER PATIENT SAMPLES Class 1 BM Class 2 BM Class 3 BM Tissue ID. BM1 BM2 BM3 Fov060265 0.69 0.79 0.73 Fov050855 0.94 0.71 0.67 Fov041300 0.89 0.23 0.55 Fov060380 0.95 0.62 0.51 Fov060050 0.85 0.23 0.51 Patient Fov041285
0.69 0.19 0.5 Fov100142 0.47 0.76 0.47 High Fov050764 0.82 0.22 0.47 Fov041267 0.4 0.36 0.36 Fov100146 0.84 0.57 0.26 Fov060382 0.44 0.45 0.22 Fov041269 0.37 0.21 0.2 Fov060302 0.29 0.22 0.15 Predicted Responder Fov020067 0.89 0.38 0.09 Fov100003
0.9 0.89 0.08 Patient with drug target dependency Fov050700 0.17 0.17 0.07 Fov050139 0.63 0.66 0.05 Fov041138 0.36 0.11 0.05 Fov060152 0.24 0.3 0.03 Fov030062 0.57 0.14 0.02 Fov060133 0.94 0.43 0.01 Fov050666 0.93 0.38 0.01 Fov060371 0.88 0.93 0
Fov020497 0.61 0.43 0 Fov010706 0.54 0.14 0 Class 1 BM Class 2 BM Class 3 BM Fov020386 0.11 0.09 0.12 Fov050734 0.11 0.06 0.08 Fov040872 0.23 0.04 0.36 Fov050659 0.29 0.01 0.02 Fov060293 0.42 0 0 Fov060210 0.1 0.1 0 Patient Fov050840 0.07 0.29 0.01
Fov040855 0.05 0 0.22 Low Fov050816 0.04 0.33 0.12 Fov060355 0.04 0.27 0 Fov010252 0.03 0.17 0.02 Fov010682 0.03 0.03 0 Fov060553 0.03 0.02 0.03 71768C3 0.02 0 0 Predicted Non-Responder Fov150230 0 0.36 0.12 Fov060308 0 0 0 Patient with no drug
target dependency efficiently excluded 15 ACRIVON THERAPEUTICS
BIOPSY STUDY 1: SUBSTANTIAL RESPONSE AND PFS BENEFIT IN PREDICTED
RESPONDERS (BLINDED, PROSPECTIVELY DESIGNED STUDY) Available pretreatment tumor biopsies from past phase 2 trials at NCI with ACR-368 in platinum-resistant ovarian cancer were obtained rd OncoSignature scores were generated
blinded to treatment outcome at Acrivon and analyzed by 3 party biostatistician in prospectively designed study PR OncoSignature Prediction: OncoSignature Prediction: SD Non-Responders Responders 1.2 PR SD PR 0.9 PR SD SD mPFS Predicted Responders
0.6 PR mPFS = 7.9 months (days) PR SD All Predicted R 238.0 SD 0.3 All Predicted NR 66.5 SD SD in predicted R 238.0 PR SD in predicted NR 108.0 PD 0.0 mPFS in R SD SD (0.3) SD Predicted Non-Responders SD PD mPFS = 2.2 months (0.6) PD ORR = 0% ORR =
47% PD mPFS in NR PD (0.9) PD SD PD PD PD SD SD SD PD SD SD SD SD SD SD SD PR PR PR PR PR PR PR 0 100 200 300 400 500 600 700 Duration (days) Result: ORR ~47%; mPFS = 7.9 months 16 ACRIVON THERAPEUTICS Tumor fractional change
TWO ADDITIONAL HIGH UNMET NEED SOLID CANCERS PREDICTED ACR -368
-SENSITIVE THROUGH HUMAN TUMOR SAMPLE SCREENING HGS Ovarian Sq. NSCLC Bladder cancer Endometrial cancer Tissue ID BM1 BM2 BM3 Tissue ID BM1 BM2 BM3 Tissue ID BM1 BM2 BM3 Tissue ID BM1 BM2 BM3 Fov010719 0.96 0.68 0.78 Rln020132 0.17 0.26 0.02
Fur021904 0.16 0.38 0.86 Ubd040512 0.99 0.48 0.65 Fov060075 0.54 0.51 0.38 Rln010099 0.08 0.06 0.01 Fur021989 0.86 0.17 0.71 Fov020069 0.31 0.30 0.38 Ubd040016 0.30 0.58 0.63 Fov010809 0.94 0.16 0.36 Rln020029 0.48 0.28 0.00 Fur021785 0.14 0.55 0.69
Fov030970 0.93 0.28 0.33 Rln020005 0.34 0.06 0.00 Ubd040039 0.43 0.33 0.54 Fur021984 0.87 0.62 0.63 Fov010892 0.95 0.72 0.32 Rln010095 0.28 0.02 0.00 Fov040102 0.98 0.23 0.29 Fur021937 0.81 0.65 0.61 Ubd030040 0.88 0.73 0.45 Fov050734 0.95 0.22 0.25
Rln020051 0.11 0.01 0.14 Fur022037 0.12 0.22 0.54 Fov040164 0.94 0.69 0.21 Ubd040287 0.63 0.34 0.40 Rln010167 0.14 0.00 0.00 Fur130035 0.55 0.48 0.50 Fov020776 0.60 0.18 0.19 Fov050764 0.77 0.35 0.17 Rln020284 0.09 0.00 0.00 Fur030113 0.90 0.65 0.31
Ubd040151 0.65 0.72 0.34 Fov060380 0.98 0.58 0.17 Rln020141 0.05 0.18 0.00 Fur020288 0.60 0.26 0.30 Fov010172 0.85 0.51 0.17 Ubd040225 0.76 0.64 0.33 Rln020032 0.05 0.01 0.00 Fov100051 0.92 0.21 0.16 Fur020281 0.21 0.57 0.27 Fov100142 0.58 0.82 0.14
Rln010199 0.05 0.06 0.03 Fur130010 0.79 0.75 0.27 Ubd040282 0.27 0.16 0.26 Fov020160 0.58 0.30 0.14 Rln020197 0.04 0.00 0.00 Fur021781 0.75 0.31 0.26 Fov010252 0.96 0.21 0.14 Ubd060279 0.29 0.13 0.16 Fov050617 0.61 0.76 0.14 Rln020250 0.04 0.00 0.00
Fur140135 0.72 0.35 0.25 Fov060302 0.24 0.29 0.13 Rln020190 0.04 0.00 0.00 Ubd030229 0.79 0.39 0.15 Fur150643 0.61 0.73 0.22 Fov050836 0.79 0.28 0.13 0.02 0.00 0.01 Fov060050 0.86 0.25 0.12 Rln020243 Fur021558 0.61 0.33 0.22 Ubd040104 0.84 0.58 0.15
Fov041285 0.50 0.15 0.11 Rln020012 0.02 0.41 0.07 Fur020131 0.73 0.57 0.18 Fov030109 0.97 0.39 0.10 Rln010148 0.02 0.05 0.06 Ubd040056 0.79 0.83 0.14 Fov020386 0.58 0.08 0.09 Fur021367 0.30 0.55 0.18 Fov020067 0.96 0.44 0.08 Rln020006 0.01 0.00 0.02
Ubd070017 0.62 0.40 0.14 Fur020506 0.94 0.68 0.17 Fov110030 0.92 0.39 0.08 Rln020296 0.01 0.00 0.00 Fur020163 0.23 0.33 0.12 Fov041267 0.44 0.39 0.06 Ubd040204 0.12 0.76 0.12 Rln020186 0.01 0.02 0.02 Fov100004 0.95 0.36 0.05 Fur130009 0.18 0.69 0.10